KIT and acute myeloid leukemia: The median OS of 40 KIT D816mut/CBFneg SM-AML and 17 evaluable KIT D816mut/CBFneg AMLdatabases patients was 5.4 (95% confidence interval, CI [1.7–9.1]) and 26.4 (95% CI [0–61.0]) months (P = 0.015), respectively.